Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study

All Primary Safety and Efficacy Endpoints Were Met; Conference Call Today at 11:00 am EDT

JERUSALEM, May 18, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), today announced positive top-line results from its Phase IIb study, designed to evaluate the safety and efficacy of its oral insulin […]

Categories: Press Releases|Tags: |

Oramed to Present at Oppenheimer Annual Israeli Conference

JERUSALEM, May 16, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Oppenheimer Annual Israeli Conference, taking place on May 22, 2016 in […]

Categories: Press Releases|Tags: |

Oramed Patent Being Granted in China for Oral Administration of Proteins

JERUSALEM, May 11, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that an official Notification of Granting Patent Right was issued for the Company’s patent for its invention titled “Methods and Compositions for Oral Administrations of […]

Categories: Press Releases|Tags: |

Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar

JERUSALEM, April 28, 2016
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar & Co. LLC, taking place on […]

Categories: Press Releases|Tags: |

Oramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent

Patent addresses platform technology for oral insulin capsule ORMD-0801

JERUSALEM, April 12, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Patent and Trademark Office (PTO) has issued a […]

Categories: Press Releases|Tags: |

Oramed Completes Phase IIb Oral Insulin Study

Top-Line Data to be Released This Quarter

JERUSALEM, April 5, 2016
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that all follow-up visits in the Company’s Phase IIb study of its oral insulin capsule, […]

Categories: Press Releases|Tags: |

Oramed Patent Granted in India for Oral Administration of Proteins

JERUSALEM, March 29, 2016
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the Company’s patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office.
About Oramed Pharmaceuticals

Oramed Pharmaceuticals […]

Categories: Press Releases|Tags: |

Oramed to Present at the BIO CEO & Investor Conference

JERUSALEM, February 4, 2016
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 18th Annual BIO CEO & Investor Conference, taking place February 8-9, 2016 in […]

Categories: Press Releases|Tags: |

Oramed Pharmaceuticals’ Shareholder Letter

JERUSALEM, January 6, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), today issued the following shareholder letter:

Dear Shareholders, 

2015 was a very significant year for us at Oramed setting the bar high for what we anticipate to be a momentous year ahead in 2016.

2015 Major Milestones […]

Categories: Press Releases|Tags: |

Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in China

JERUSALEM, December 29, 2015 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced the closing of its previously-announced license and investment deal with Hefei Tianhui Incubation of Technologies Co. Ltd. (“HTIT”). Oramed has sold 1,155,367 restricted shares of […]

Categories: Press Releases|Tags: |